Background {#Sec1}
==========

Acute kidney injury (AKI) is common in hospitalized patients and is independently associated with increased risk of morbidity, mortality and length of stay \[[@CR1], [@CR2]\]. AKI also leads to long-term kidney sequelae, such as chronic kidney disease (CKD), end stage renal disease (ESRD) and has long-term adverse cardiovascular effects \[[@CR3], [@CR4]\]. In the United States, AKI is one of the most serious and common health complications, occurring commonly in hospitalized patients and those in critical care settings \[[@CR5], [@CR6]\]. For these reasons, accurate risk stratification/classification of AKI and its effect on long-term complications are of prime importance.

Efforts have been made to define and classify AKI for use in clinical practice and research. Beginning with risk injury failure loss end stage (RIFLE) staging system, followed by the acute kidney injury network (AKIN), and most recently, the kidney disease improving global outcomes(KDIGO), these classification systems all assess the magnitude of serum creatinine elevation (change from baseline to peak creatinine) as the primary dimension to grade severity. AKIN and KDIGO do incorporate tempo for the rate of increase as a prerequisite (rise must occur over a period of 48 h) but none of the current classification systems take into account the duration of AKI, which reflects time to recovery and could be an additional important dimension of AKI severity.

Some studies have suggested that the duration of AKI may be an important additional or independent prognostic marker of long-term mortality, progression to CKD/ESRD and cardiovascular outcomes in patients with AKI in different clinical settings \[[@CR7]--[@CR15]\]. Furthermore, duration of AKI has also been suggested as a better endpoint for trials of AKI \[[@CR16]\]. However, there has not been any systematic review or meta-analysis to quantify pooled estimates from these disparate studies. Therefore, we performed a systematic review and meta-analysis of the literature assessing impact of duration of AKI on survival, progression to CKD and cardiovascular outcomes.

Methods {#Sec2}
=======

This study was performed in accordance with published guidelines for systematic review, analysis, and reporting for meta-analysis of observational studies \[[@CR17]\].

Inclusion and exclusion criteria {#Sec3}
--------------------------------

Studies were included if they provided information about duration of acute kidney injury in hospitalized patients. The settings for hospitalization included: 1. Medical non intensive care; 2. surgical non intensive care-not post-surgical; 3. Medical-intensive care; 4. surgical intensive care-not post-surgical; 5. surgical intensive care-post surgical-cardiac surgery and 6. Surgical intensive care-post surgical-non cardiac surgery and reported at least one of the outcomes: short or long term mortality, cardiovascular outcomes and progression to chronic kidney disease (CKD) or end stage renal disease (ESRD). Observational studies (prospective cohort (PC) / retrospective cohort (RC) / evaluating human adult patients with age ≥ 18 years admitted to the hospital with AKI were included. There was no publication year restriction. We excluded in vitro / in vivo studies, case reports / case series, narrative reviews, book abstracts, editorials / authors' replies, and systematic reviews / meta-analyses (after scanning references for relevant articles) and non-English articles.

Literature review and study selection {#Sec4}
-------------------------------------

A comprehensive search query employing a combination of appropriate subject headings and keywords was developed in collaboration with a qualified medical librarian. The search was executed in the MEDLINE, Embase, Cochrane Library, CINAHL and Web of Science databases from database inception through December 2015. Animal studies were excluded using the search statement recommended by the Cochrane Collaboration. The full electronic search strategy for all databases is available in Additional file [1](#MOESM1){ref-type="media"}. An additional 123 citations, identified using PubMed's Similar Articles algorithm and after reviewing the references of included articles to identify additional articles, were included in the screening library.

Search results were independently screened by two reviewers (SM, SP). In the case of disagreement among reviewers, a third reviewer (GN) arbitrated. Study selection occurred in two successive rounds, the first round based on titles and abstracts, the second round based on full text.

Data collection {#Sec5}
---------------

Two review authors (SM,SP) independently extracted relevant study characteristics and outcomes from the included studies using a standardized and piloted data extraction form. The information extracted from each study was: author, year of publication, characteristics of participants (number, age and sex), clinical setting, type of study (prospective vs retrospective), study period and follow up, definition and severity of AKI, duration of AKI and incidence of outcomes (Long term mortality, cardiovascular events and progression to CKD and ESRD) amongst participants with different duration of AKI. AKI was ascertained either by using the standard AKIN/KDIGO/ RIFLE criteria or AKI (increase in serum Creatinine of at least 25--30% of baseline) vs no AKI and ATN (Sudden rise in serum Creatinine to more than 2 mg/dl in subjects with prior normal renal function) vs no ATN. Due to significant heterogeneity of definitions of duration of AKI, we created the following 3 categories of duration of AKI: "Short" if AKI duration was ≤2 days or labeled as "transient AKI"; "Medium" for AKI durations 3--6 days and "Long" for AKI duration of ≥7 days or "persistent /non-recovered". Any discrepancies about date extraction were resolved by a third reviewer (GN). The study was conducted through August 2015 to June 2016.

Quality assessment {#Sec6}
------------------

Two independent reviewers assessed study quality according to criteria outlined by Downs and Black using the 27-point checklist included within 5 main sections \[[@CR18]\]. The five sections include questions about: 1. Reporting (10 items); 2. External validity (3 items); 3. Internal validity/Bias (7 items); 4. Confounding (selection bias) (6 items); and 5. Power of the study (1 item).

Studies were graded as good quality if scored 20 or higher, fair quality if scored 15 or higher and poor quality with below 14 scores in the checklist. Please refer to Additional file [2](#MOESM2){ref-type="media"} for details.

Outcome measures {#Sec7}
----------------

Primary outcome measures were the adjusted risk ratio (RR) for long-term mortality associated with AKI duration. We also aimed to compare effect sizes of associations to standard AKIN/KDIGO Stages. Secondary outcomes were the risk for cardiovascular outcomes and incident CKD. In two of the studies with cardiovascular outcomes - the cardiovascular events were de novo, \[[@CR10], [@CR19]\] while one study included pts. with prior cardiac disease and then aimed at determining the association of duration of AKI and risk for CV events beginning 90 days after discharge \[[@CR11]\]. We also assessed the adjusted RR for cardiovascular outcomes and incident CKD stage 3 with duration of AKI when stratified within each stage of AKI.

Statistical analysis {#Sec8}
--------------------

Random effects meta-analysis was conducted to estimate the magnitude of risk associated with duration of AKI for each outcome, as measured by combined adjusted RR with 95% confidence intervals. Adjusted risk estimates included those published in final multivariate models for each study, which considered confounding from sociodemographic and clinical covariates, such as age, gender, race, co-morbidities, medications, and laboratory values. Adjusted pooled risk ratios for duration of AKI were estimated with inverse variance method using Review Manager 5.3. We formally assessed heterogeneity of effects between studies with the I^2^ Statistic.

Results {#Sec9}
=======

We identified 8864 studies meeting our search criteria. After excluding 2071 duplicate and 425 non-English studies, 6368 were evaluated, and 270 were selected for full text review. After application of exclusion criteria 18 studies were deemed eligible for this systematic review (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Prisma flow diagram of studies that were considered for inclusion

Study and patient characteristics from the selected articles are summarized in Table [1](#Tab1){ref-type="table"}. These 18 studies were comprised of 459,558 patients with length of follow-up-median,3 years; IQR,1.8 to 4.75 years. Baseline Cr definition varied-Most studies defined baseline Cr as value recorded just prior to surgery or hospitalization, 1 study \[[@CR20]\] defined it as- mean of all outpatient Cr in 6 months before hospitalization, 1 study \[[@CR19]\] as Serum Cr less than 1.4 mg/dl.Table 1Characteristics of studies included in the systematic review and meta-analysisFirst AuthorYearSingle vs. Multi\
CenterType of StudyClinical SettingNYears of Follow UpAge RangePercent\
MaleLength of Hospital Stay in Days^a^AKI definition severityDuration of AKIStudy QualityDifferent covariates adjusted forMeanMaxShort, medium or longTransient or PersistentBrown2010SingleRCardiac surgery49872.6564--7229--336--24.AKIN√Fairage, sex, prior CABG, COPD, emergency surgery, ejection fraction and baseline eGFRCoca \[[@CR7]\]2010MultiRNon cardiac35,3023.8966--8896--986AKIN√Goodage, sex, race, chronic insulin use, operative time, ASA class 4/5, emergency surgery, baseline GFR, smoking status,weight loss \> 10% last 6 months, chronic alcohol intake, COPD, pre-op albumin, hematocrit,WBC, and hemoglobin A1CChoi \[[@CR11]\]2010MultiRGeneral Hospital17,3255.72044--4798NMAKIN√FairAge, sex, race, baseline GFR, albuminuria, viral load, cd4, htn, dm, lung ds, smoking, cancer, ICU admissionGoldberg \[[@CR19]\]2009SingleRPost MI19571.5559--7076NMAKIN√Fairage, gender, estimated GFR (MDRD), previous diuretic therapy, HTN,DM, smoking, previou MI, heart rate and blood pressure on admission, use of reperfusion therapy ACE/ARB and beta-blockers), and left ventricular EF.,Han \[[@CR12]\]2013SingleRICU21430.40.56852--6813--29KDIGO√FairAge, sex, Apache, primary diagnosis, underlying CKD, history of malignancy, the need for mechanical ventilation, the use of vasoactive drugs, and AKI stagesLoef \[[@CR26]\]2004SingleRCardiac surgery8438.362--64731--5AKI/\
No AKIFairAge, PVD,Operation time, pre op renal function by cockroft-gault formula,post op renal function deteriorationTRIBE-AKI \[[@CR21]\]2016MultiPCardiac surgery1199371--7366--767--32AKIN√GoodAge, sex, race, elective surgery, preop GFR, DM, HTN, CHF, MI,surgery type and centerWu \[[@CR14]\]2015SingleRIntensive318865.67131KDIGO√Goodage, gender, need for a ventilator, emergent operation and baseline renal function; severity of sepsis, the use of vasoactive drugs and diuretics, surgery category; APACHE II, MODS, SOFA scores and peak KDIGO stage.Yoo \[[@CR13]\]2014SinglePGeneral Hospital1230.653.464.86139AKIN√GoodAge, sex, charlson comorbity index, recoveryPannu \[[@CR20]\]2013MultiRGeneral Hospital190,7142.8663--6647--53NMKDIGO√Goodage, sex, MI, PVD,CVA,CHF,DM, nondermatologic malignancy, baseline estimatedGFR,requirement for acute dialysis, primary diagnostic code for hospitalization, CIHI resource intensity weight.Liano \[[@CR19]\]2006SingleRGeneral Hospital4137.22257.86654ATN/\
No ATN√PoorAge, sex, type of admission, ATN etiology, need for RRT, ARF functional severity, ICU admission,incidence of comorbity factorsUchino \[[@CR27]\]2010SingleRGeneral Hospital20,126265--7849--56NMRIFLE√FairAge, sex, emergency admission, ICU admission,mech ventilation,baseline Cr in mg/dl,operation timeWamock \[[@CR28]\]2015SingleRGeneral Hospital50,580285555--634--8AKI/\
No AKI√FairAge, race, sex, charlson comorbid index, admission source, egfr \< 60Gammelager \[[@CR10]\]2014MultiRICU21,5502.7357--6853--618--23KDIGO√Fairage, gender, other ischemic heart diseases, CVA,HTN, PVD, CKD cancer, surgical status, primary diagnosis during current hospitalization, and preadmission use of drugsWelton \[[@CR29]\]2007SingleRCardiac surgery13246106680NMAKI/\
No AKI√GoodAge, sex, HTN, DM, smoking,Hl, COPD, BMI,Prior MI and coronary revascularization,angina, CHF, baseline Cr Clearance, medications, and short term complications.Heung \[[@CR9]\]2015SingleRGeneral Hospital104,7641361.8957KDIGO√GoodAge, race, sex, preadmission,DM, HTN,Dx of sepsis, need for mechanical ventilation during index hospitalization, length of stay,charlson comorbity score and baseline GFR.Sood \[[@CR30]\]2014multiRICU54430055--7057NMRIFLE√GoodDemographics, illness severity, co-morbidity,and treatmentPerinel \[[@CR31]\]2015multiRICU4470045--7563.3NMAKIN√GoodAge, type of AKI, use of vasopressors, illness severity*R* Retrospective, *P* Prospective, *AKIN* Acute Kidney Injury Network, *HIV* Human Immunodeficiency Virus, *NM* Not Mentioned, *ICU*- Intensive Care Unit, *KDIGO* Kidney Disease: Improving Global Outcomes, *ATN* Acute Tubular Necrosis, *RIFLE* Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease classification, *AMI* Acute myocardial infarction, *DM* Diabetes Mellitus, *HTN* Hypertension, *PVD* Peripheral vascular Disease, *CHF* Congestive heart failure, *MI* Myocardial infarction, *BMI* Body mass index, *CVA* Cerebrovascular accident, *Dx* Diagnosis, *Cr* Creatinine^a^Median days of length of hospitalization as reported by authors

Duration of AKI was defined as either short (≤ 2 days), medium (3--6 days) or long (≥ 7 days)or transient(renal recovery at hospital discharge with Cr returning to either baseline or atleast within 25--50% of baseline without requirement of renal replacement therapy during hospitalization) and persistent/non recovered(no renal recovery at hospital discharge and not meeting above criteria). 7 out of 16 studies categorized duration of AKI as short, medium or long and the remaining 11 studies categorized AKI as transient vs. persistent. 17 out of 18 studies met the quality criteria, were fair to good quality (Table [1](#Tab1){ref-type="table"} and Additional file [2](#MOESM2){ref-type="media"}). The definitions of AKI severity varied substantially (Table [1](#Tab1){ref-type="table"}) 14 out of 18 studies defined AKI using standard AKIN/RIFLE and KDIGO definitions. 3 studies defined AKI as increase in serum Creatinine of at least 25--30% of baseline and the remaining one study used AKI as synonymous with ATN defining it as sudden rise in serum Creatinine to more than 2 mg/dl in subjects with prior normal renal function**.** The overall incidence of AKI was 15%, and of those with AKI in the 7 studies that stratified duration as short, medium and long, 68% experienced short duration, 17% medium duration, and 13% long duration AKI. Then for remaining 11 studies, 60% experienced transient and 40% experienced persistent or non-recovered AKI. 8 out of 18 studies had approximately 5.32% subjects requiring renal replacement therapy amongst long duration or persistent AKI. We then grouped transient with short duration of AKI and persistent or non-recovered AKI with long duration of AKI in order to align participants by duration of AKI. The most common clinical setting for the studies of AKI duration was general hospitalized patients (*n* = 6), cardiac surgery (*n* = 5) and critical illness (n = 5). Most studies were single center (*n* = 11) and retrospective (*n* = 16).

Duration of AKI and long-term mortality {#Sec10}
---------------------------------------

The outcomes of long-term mortality with duration of AKI were reported in 8 studies. Three of the eight studies \[[@CR7], [@CR8], [@CR21]\], reported risk for mortality for duration of AKI stratified within each stage of AKI 1, 2 and 3, as defined by peak changes in creatinine. Long term mortality generally was higher for longer duration of AKI: short duration of AKI (*n* = 8 studies, RR 1.42, 95% CI 1.21--1.66; Fig. [2a](#Fig2){ref-type="fig"}), medium duration (*n* = 4 studies, RR 1.92, 95% CI 1.34--2.75; Fig. [2b](#Fig2){ref-type="fig"}), and long duration (n = 8 studies, RR 2.28, 95% CI 1.77--2.94; Fig. [2c](#Fig2){ref-type="fig"}) of AKI. There was considerable heterogeneity across pooled studies.Fig. 2Pooled RRs for long term mortality by short (**a**), medium (**b**) and long (**c**) duration of AKI

We also made separate forest plots for short, medium and long duration and transient(recovered) and persistent (non recovered) AKI. Even with separate forest plots, the pooled Risk Ratio (RR) for long-term mortality generally was higher for longer duration of AKI or Persistent (non recovered) AKI. Please refer to Additional files [3](#MOESM3){ref-type="media"} and [4](#MOESM4){ref-type="media"} respectively.

Duration of AKI and association with long-term cardiovascular outcomes {#Sec11}
----------------------------------------------------------------------

Three studies reported on cardiovascular outcomes, including congestive heart failure (CHF) and myocardial infarction (MI), in association with differing durations of AKI. Duration of AKI added additional prognostic value to AKIN stages of AKI for the outcome of CHF (Fig. [3a, b, c, d](#Fig3){ref-type="fig"}) and duration of AKI added additional prognostic value in patients with stage 2 or 3 AKI for the outcome of MI, but not for those with stage 1 AKI (Fig. [4a, b, c](#Fig4){ref-type="fig"} and [d](#Fig4){ref-type="fig"}).Fig. 3RR for CHF by duration within strata of AKIFig. 4RR for MI by duration within strata of AKI

Duration of AKI and incident CKD {#Sec12}
--------------------------------

Two studies reported on the risk for CKD in association with the duration of AKI. Heung et al. examined 104,764 veterans with baseline eGFR \> 60 mL/min/1.73 m^2^ and demonstrated a dose-response relationship between the duration of AKI and the risk for development of CKD stage 3 stratified across all AKI stages (Fig. [5](#Fig5){ref-type="fig"}) \[[@CR9]\]. Palomba et al. examined the risk for CKD after cardiac surgery, and found that those with AKI duration \> 3 days had an adjusted OR for incident CKD of 13.5 (95% CI 4.2--43.7) \[[@CR22]\].Fig. 5Risk for incident CKD stage 3 increases with duration even after adjusting for KDIGO stage

Discussion {#Sec13}
==========

This is the first systematic review and meta-analysis to date that summarizes the association of duration of AKI with several important outcomes. While there was heterogeneity across studies due to different study design and definitions of AKI and schema of classifying duration, the results suggest consistently and strongly that there is a dose-response relationship between duration of AKI and long-term outcomes, including death, cardiovascular outcomes, and incident CKD.

The current consensus definitions of AKI as proposed by AKIN/KDIGO or RIFLE do not incorporate any duration component into the definitions. However, based on the available data summarized in this manuscript, it appears that the duration of AKI provides additive risk information for long-term outcomes among survivors after hospitalization with AKI. While few studies accounted for the severity of AKI by existing definitions and assessed the additional independent contribution of duration, there was a strong independent signal for outcomes, particularly in the studies that assessed CV events and incident CKD. Our study emphasizes that patients with AKI stages 2 and 3 are at increased risk of CHF and MI, however, the risk is more pronounced in patients without recovery of renal function. This may suggest a need for systematic follow up of patients discharged after an AKI episode, especially those who did not regain their renal function before discharge \[[@CR9]--[@CR11], [@CR23]\].

Based on the above findings of our systematic review and meta-analysis, we propose that the duration of AKI should be incorporated into future schemas for classification of AKI for prognosis of long-term outcomes. Most of the studies on long-term prognosis after AKI mostly focus on characterizing the severity of AKI by magnitude of rise in serum creatinine, but hopefully this systematic review will encourage clinical researchers and epidemiologists to use at least two-dimensional approaches (magnitude of serum creatinine rise and duration of AKI) to evaluate outcomes of AKI for future investigations. However, recently long-duration of AKI / persistent AKI is equivalent to the new term of Acute kidney disease(AKD). AKD is a newly recognized term by the Acute dialysis quality initiative (ADQI) in their consensus report \[[@CR24]\] that recognizes the important consequences of AKI duration of 7 days or more (ARD).

This review also focuses attention on the fact that a patient who experiences a large but transient increase in serum creatinine is prognostically different from patient who experiences a sustained increase in serum creatinine. While the current classification of AKI assigns higher risk to the first patient given the rise in creatinine is numerically higher, the findings suggest that the second patient has equal or higher risk of worse outcomes. Further research is needed as how to effectively treat such patients and whether close follow up of these patient's post- hospital discharge improves outcomes.

Duration of AKI could be similar to or atleast an overlap to the concept of "kidney recovery" at hospital discharge. Recently, Kellum et al. \[[@CR25]\] characterized various patterns of kidney recovery after an episode of AKI and related these patterns to long term outcomes. They found that early reversal was associated with the shortest ICU stay and best prognosis, 1-year survival, 90.2% and those who never recovered or had reversal with relapse had the worst prognosis, 1-year survival, 40%. These results are similar to our findings of longer duration of AKI with worse long-term mortality.

The findings herein have additional implications with regards to clinical trials. Using mathematical modeling of creatinine changes in AKI, it has been suggested that incorporating time to creatinine elevation into AKI definitions may be a more efficient and a less biased way of ascertainment of outcomes in interventional trials for AKI \[[@CR16]\]. Therefore, one could propose that AKI duration should be considered to improve the endpoints for phase 2 trials of new agents instead of just incident AKI by peak creatinine as an outcome. The downside of using incident AKI as an outcome is that an investigational drug/therapy will have to work at a particular time point or earlier (for example in pre-renal phase of Acute Tubular Necrosis, ATN) to reduce AKI incidence. In contrast, if duration of AKI is employed as an outcome, one can show the intervention to be effective if it works on any of the phases of ATN (initiation, propagation, maintenance, and recovery phases), thereby decreasing duration of AKI. Moreover, long duration of AKI might serve as an enrollment criterion for interventions that aim to abrogate the transition from AKI to CKD.

Strengths and limitations {#Sec14}
-------------------------

The strengths of this analysis include adequate length of follow up in the studies which looked at long term mortality, cardiovascular outcomes and incident CKD stage 3 and rigorous study selection and pooling of only adjusted estimates. Also, the results of the study could be generalized to various clinical settings and to varying populations. Despite above, our study should be interpreted in light of some limitations. Although, we performed an exhaustive search of the literature for duration of AKI studies, publication bias cannot be ruled out. It is possible that smaller negative studies were not published. We considered formally assessing publication bias through a funnel plot; however, funnel plots cannot be interpreted in the presence of marked heterogeneity. Another important limitation is the heterogeneous definition of duration of AKI used in different studies enabling us to group transient with short duration of AKI and persistent or non-recovered AKI with long duration of AKI in order to align participants by duration of AKI. However, this resulted in a high degree of statistical heterogeneity. Also, there were only two studies published that associated AKI duration with subsequent CKD and there is lack of data on the outcome of ESRD. As for most of the meta-analysis, our meta-analysis is also limited by the quality of the primary studies. Only 7 studies were graded as good quality with the primary limitation in other studies being the internal validity-bias (Additional file [2](#MOESM2){ref-type="media"}). The association between duration of AKI and outcomes is also highly prone to be a surrogate for severity of illness. While the studies adjusted for known confounders, certainly residual confounding was present and could not be eliminated, thus potentially biasing the point estimates away from null. Lastly, the population in the study was mostly male, whether the same findings apply to females is unknown and should be the subject of further investigation.

Conclusion {#Sec15}
==========

In conclusion, duration of AKI is independently associated with long-term mortality and may provide additional prognostic information over and above magnitude of serum creatinine alone. Thus, AKI duration can be considered as a prognostic factor for long-term mortality and other cardiovascular outcomes and can be used as an endpoint in intervention trials to prevent or treat AKI.
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